Approvals include CONFIENT(TM) ICD, LIVIAN(TM) CRT-D and upgraded
LATITUDE(R) Patient Management System
NATICK, Mass., Feb. 25 /PRNewswire-FirstCall/ -- Boston Scientific
Corporation (NYSE: BSX) today announced U.S. Food and Drug Administration
(FDA) approval for three products in its Cardiac Rhythm Management
business. They are:
-- The CONFIENT(TM) implantable cardioverter defibrillator (ICD), which
helps protect patients at risk of sudden cardiac death
-- The LIVIAN(TM) cardiac resynchronization therapy defibrillator
(CRT-D), which provides cardiac resynchronization and defibrillation
therapies in one device
-- An upgraded LATITUDE(R) Patient Management System, with enhanced
remote monitoring capabilities
"Our Cardiac Rhythm Management (CRM) team is refocused on delivering therapy systems that meet physicians' needs for safety, reliability and better patient outcomes," said Jim Tobin, President and Chief Executive Officer of Boston Scientific. "These and other recent approvals are tangible examples of the team's revitalized commitment to quality and innovation."
The CONFIENT ICD features an enhanced AV (atrial ventricular) Search Hysteresis feature designed to reduce unnecessary right ventricular pacing. The device is equipped with wireless capability designed to save physicians time during implant by allowing device programming during wound closure and eliminating the need for the programming wand in the sterile field. Wireless capability also saves time at follow-up visits by offering device interrogations that can be three times faster than the Company's wanded telemetry.
|SOURCE Boston Scientific Corporation|
Copyright©2008 PR Newswire.
All rights reserved